Perrigo has announced that Endo Pharmaceuticals filed a patent suit on March 1, 2019 in the United States District Court for the District of Delaware in response to a Perrigo ANDA for a generic version of Nascobal cyanocobalamin nasal spray.
Nascobal was originally approved by the FDA in 2015. The Orange Book lists 6 patents for Nascobal nasal spray, all with expiration dates in 2024.
Perrigo Executive VP and President Rx Pharmaceuticals Sharon Kochan commented, “This ANDA filling and subsequent patent challenge further demonstrates our commitment to enhance our pipeline and product offering in the extended topical space. Our R&D, operations, quality and legal teams worked diligently to develop and introduce new high quality generic products that lower the cost of healthcare.”
Read the Perrigo press release.
